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In the previous issue of Critical Care, Mori and colleagues demonstrate that glutamine supplementation in
mechanically ventilated patients as part of parenteral nutrition increases plasma glutamine concentration and
glutamine utilization, but does not mitigate protein degradation and even increases de novo glutamine production.
Studies suggest that protein degradation is regulated by the degree of inflammation. Immune cells utilize large
amounts of glutamine and derive their glutamine requirements from muscle protein degradation. We hypothesize
that the effects of glutamine supplementation depend on the degree of inflammation. Infusing large amounts of
exogenous glutamine into patients with inflammatory conditions like sepsis and multiple organ failure may not
only enhance immune competence, but may potentially augment the inflammatory response and thereby
negatively influence outcome.Introduction
Critical illness confers muscle wasting. Skeletal muscle
serves as a source of amino acids, especially glutamine,
for energy and substrates for immune and other cells.
Glutamine is considered conditionally essential and sup-
plementation has been used to maintain muscle and
immune function during critical illness. In the previous
issue of Critical Care, Mori and colleagues present
their study evaluating effects of intravenous dipeptide
L-alanyl-L-glutamine (0.28 g/kg during 20 hours) supple-
mentation on glutamine metabolism [1]. They hypothe-
sized that exogenous glutamine supplementation would
increase plasma glutamine concentrations and thereby at-
tenuate endogenous glutamine production. Contrary to
their expectation and, although plasma concentrations
increased, glutamine appearance rate increased by 14%.
Protein degradation was not attenuated as hypothesized.
The increased glutamine appearance was due to increased
endogenous glutamine production, while the infused glu-
tamine was 'utilized' and did not inhibit proteolysis.
These results add to the confusion around glutamine
supplementation. In addition to the lack of effect of* Correspondence: hmoudemans@gmail.com
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2014glutamine supplementation on protein degradation in this
study, glutamine supplementation even increased mortal-
ity in the recent and largest randomized controlled trial in
critically ill patients up to now [2]. Of note, the latter used
extremely high dosages of glutamine in ICU patients with
multiple organ failure, while nutrition was hypocaloric.
Does the study of Mori and colleagues provide a clue?Immune cells, muscle and glutamine
We revisited older publications [3,4] describing that glu-
tamine is highly utilized by lymphocytes, mainly as a
source of nitrogen and carbon precursors for synthesis of
macromolecules such as purines 3 and pyrimidines for
DNA and RNA, and less so as a fuel through complete
oxidation. Moreover, lymphocytes utilize glutamine at
rates markedly in excess of what is needed for energy and
precursors. The authors postulate a likely purpose of this
seemingly futile cycling. High rates of glutaminolysis pro-
vide ideal conditions for the provision of intermediates for
pathways when required under conditions of increased
need, such as rapid immune cell proliferation, indepen-
dent of the momentary glutamine availability. Glutamine
availability for this high rate of glutaminolysis in rapidly
dividing immune cells is provided via proteolysis in mus-
cles. Furthermore, if lymphocytes are activated, the rate of
glutaminolysis is further increased [5]. In vitro studiesen; licensee BioMed Central Ltd. The licensee has exclusive rights to distribute
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interleukin-1 production by macrophages depends on glu-
tamine concentration (summarized in [4]). This hypoth-
esis could be extrapolated. Infusing large amounts of
exogenous glutamine into patients with inflammatory
conditions like sepsis and multiple organ failure may not
only enhance immune competence, but may potentially
augment the inflammatory response and thereby nega-
tively influence outcome. This ‘inflammation hypothesis’
may explain the seemingly contradictory results of studies
on glutamine supplementation: positive results in the pre-
and perioperative settings or in ICU patients on prolonged
parenteral nutrition [6-11], and neutral [12] or negative
results [2] when administered during the acute phase of
inflammation or severe multiple organ failure.
Interpretation
The results of the study by Mori and colleagues support
this concept [1]. They demonstrated that protein degrad-
ation was independent of glutamine plasma concentra-
tions. Protein degradation is likely controlled by the
degree of inflammation. Although the additional exogen-
ous glutamine initially increased plasma concentrations, it
was utilized thereafter. No insight is provided as to which
cells utilized the additional glutamine, but these could be
immune, liver or gut cells. Kao and colleagues [13] investi-
gated glutamine metabolism in sepsis and specifically its
conversion to citrulline in the gut. They found that
splanchnic glutamine extraction was similar in (fasting)
patients with sepsis compared to controls, while leucine
extraction was increased. They also found that uptake of
glutamine by enterocytes was decreased and the fraction
used for conversion to citrulline was diminished. Thus,
the lower glutamine concentrations in these septic pa-
tients were due to increased clearance by the liver and/or
other cells, while intestinal uptake was decreased. These
findings confirm previous observations in sepsis showing
decreased glutamine utilization by the gut [14]. In con-
trast, in non-septic patients, glutamine supplementation
showed beneficial effects on gut mucosa integrity and
barrier function [6,7]. The increased glutamine utilization
in the study by Mori and colleagues was likely due to up-
take by immune cells. The increased de novo synthesis
may be attributed to an increase in glutaminolysis by
glutamine-activated immune cells, which derive glutamine
via de novo glutamine production.
Conclusion
Glutamine supplementation in ventilated patients did not
decrease muscle protein breakdown and even increased
de novo glutamine production in the study by Mori and
colleagues. The reason for this may be that protein
degradation depends on the degree of inflammation. The
rapidly dividing immune cells and the liver are the mainconsumers of glutamine in sepsis, while glutamine
utilization in the gut is inhibited. Immune cells derive
their increased glutamine requirements from muscle pro-
tein degradation, which seems to be regulated by glutami-
nolysis in immune cells and thereby by inflammatory
stimuli. Glutamine supplementation does not mitigate this
process. Supplemented glutamine may even stimulate
lymphocyte proliferation and cytokine production and
thereby increase immune cell glutaminolysis. Increased
de novo synthesis of glutamine is essential to support these
high rates of glutaminolysis. We hypothesize that, although
beneficial effects of glutamine provision have been reported
in patients following surgery, trauma, burns or bone mar-
row transplantation [9-11], glutamine infusion in patients
with sepsis or multiple organ failure may further enhance
the inflammatory response. Interference of glutamine me-
tabolism in this complex inflammatory process may have
unpredictable effects and further studies are warranted to
unravel glutamine metabolism in critically ill patients to
avoid harm and select patients that may benefit from
supplementation.
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